Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
CVKD Stock Chart & Stats
$12.92
-$1.27(-7.12%)
At close: 4:00 PM EST
$12.92
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$4.21 - $19.03
Previous CloseN/A
Volume16.20K
Average Volume (3M)55.78K
Market Cap
$9.94M
Enterprise Value$7.96M
Total Cash (Recent Filing)$4.01M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,338,127
10 Day Avg. Volume54,835
30 Day Avg. Volume55,782
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.38
Price to Sales (P/S)0.00
P/FCF Ratio-2.40
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.35K
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$45.00Price Target Upside248.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Expansion — First‑in‑class 12‑LOX ProgramAcquiring a selective 12-LOX portfolio materially broadens Cadrenal's clinical optionality. A differentiated, first‑in‑class mechanism opens multiple indication paths (HIT and metabolic inflammation), strengthens long‑term R&D runway and supports a focused Phase 3/regulatory strategy.
Positive Phase 2 Signal On Thrombotic EventsAlthough underpowered, the reduction in thrombotic events is a durable clinical signal that supports CAD-1005’s mechanism. This secondary efficacy evidence can de-risk a registrational design, inform FDA discussions, and underpin commercial potential in an area with unmet randomized evidence.
Low Financial LeverageA near-zero debt load provides structural financial flexibility: lower fixed obligations, no interest burden, and the ability to structure non‑debt financing or partnerships. This reduces insolvency risk while management pursues costly clinical milestones over coming quarters.
Bears Say
Sustained Cash BurnPersistently negative operating cash flow and accelerating burn create structural financing risk. Ongoing trial programs will require external capital raises or partnerships, which can dilute shareholders, constrain strategic choices, and place pressure on timelines if funding gaps emerge.
Eroding Equity BaseA materially reduced equity buffer signals sustained capital consumption and likely prior dilution. This weakens balance‑sheet resilience, limits ability to self‑fund larger trials, and increases the probability of further equity financings under potentially dilutive terms.
No Revenue; Very Small Operational ScaleAs a tiny, pre‑revenue clinical company with only a handful of employees, Cadrenal faces concentrated execution risk. Successful commercialization requires significant organizational buildout, partnerships or outsourcing and reliable clinical outcomes to transition from research to sustainable operations.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $4.21 and its highest was $19.03 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $9.94M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 36 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,338,127 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$45.00
▲(248.30% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
16.94% Insiders
2.36% Mutual Funds
1.08% Other Institutional Investors
77.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---